Compare · LHDX vs TMDX
LHDX vs TMDX
Side-by-side comparison of Lucira Health Inc. (LHDX) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LHDX and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX carries a market cap of $3.20B.
- TMDX has hit the wire 8 times in the past 4 weeks while LHDX has been quiet.
- TMDX has more recent analyst coverage (20 ratings vs 0 for LHDX).
- Company
- Lucira Health Inc.
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- -
- $3.20B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 20
Lucira Health Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest LHDX
- SEC Form 15-12G filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership
- SEC Form NT 10-Q filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Lucira Health Inc.
Latest TMDX
- Director Tobin James R sold $385,464 worth of shares (4,059 units at $94.97), decreasing direct ownership by 58% to 2,922 units (SEC Form 4)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Third Quarter 2026 Financial Results
- Officer Araujo Fernando N. was granted 22,969 shares (SEC Form 4)
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at Upcoming Investor Conferences
- TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Barclays initiated coverage on TransMedics Group with a new price target